Sign up USA
Proactive Investors - Run By Investors For Investors

Genprex CEO updates investors on recent $10mln capital raise, progress of cancer-fighting drug Oncoprex

Genprex (NASDAQ:GNPX) CEO Rodney Varner updates Proactive's Christine Corrado on the Austin, Texas-based biopharma's operations in the last few months, notably raising $10mln to be used toward continuing the company's clinical trial of Oncoprex,. Enrollment in Phase 1 and 2 studies for the cancer fighting drug has resumed. Varner also talks about Genprex's agreement with the University of Texas MD Anderson Cancer Center.

Varner is in New York to speak to investors at the H.C. Wainwright & Co. 20th Annual Investor Conference.

View full GNPX profile View Profile

Genprex, Inc. Timeline

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use